Therapeutic Advances in Infectious Disease (Oct 2021)

SARS-CoV-2 RNA in the Cerebrospinal Fluid of a Patient with Long COVID

  • Daša Viszlayová,
  • Martin Sojka,
  • Silvia Dobrodenková,
  • Szabolcs Szabó,
  • Ondrej Bilec,
  • Mária Turzová,
  • Juraj Ďurina,
  • Barbara Baloghová,
  • Zoltán Borbély,
  • Martin Kršák

DOI
https://doi.org/10.1177/20499361211048572
Journal volume & issue
Vol. 8

Abstract

Read online

Over 10% of COVID-19 convalescents report post-COVID-19 complications, namely, ‘long COVID’ or ‘post-COVID syndrome,’ including a number of neuro-psychiatric symptoms. The pathophysiology of COVID-19 in the central nervous system is poorly understood but may represent post-COVID injury, ongoing sterile maladaptive inflammation, or SARS-CoV-2 persistence. We describe a long COVID patient with SARS-CoV-2 RNA in the cerebrospinal fluid, which seems important, specifically due to recent reports of gray matter volume loss in COVID-19 patients. Further studies of SARS-CoV2 RNA, markers of inflammation, and neuronal damage in the CSF of patients with long COVID would be useful and should address whether the CNS can serve as a reservoir of SARS-CoV-2, clarify the pathway by which COVID-19 contributes to CNS dysfunction, and how best to therapeutically address it.